Beam Therapeutics (BEAM) Interest & Investment Income (2019 - 2026)

Beam Therapeutics (BEAM) has reported Interest & Investment Income for 8 consecutive years, with $9.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income changed 0.03% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $43.7 million (down 7.16% YoY), while the FY2025 annual figure was $43.7 million, down 10.92% from the prior year.
• Interest & Investment Income slipped to $9.9 million in Q1 2026 per BEAM's latest filing, from $10.6 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $14.2 million in Q2 2024 and bottomed at $644000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $9.7 million across 5 years, with a median of $10.9 million in 2025.
• Annual changes were most pronounced in 2022 — Interest & Investment Income soared 55255.56% — and 2025, when it fell 16.75%.
• Beam Therapeutics' Interest & Investment Income stood at $7.6 million in 2022, then surged by 58.51% to $12.1 million in 2023, then fell by 9.42% to $10.9 million in 2024, then fell by 2.64% to $10.6 million in 2025, then dropped by 7.27% to $9.9 million in 2026.
• Business Quant data shows BEAM's Interest & Investment Income at $9.9 million in Q1 2026, $10.6 million in Q4 2025, and $10.9 million in Q3 2025.